This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Compound Derived from Marijuana May Benefit ... In recent years, cannabinoids—the active chemicals ... (20 Nov 2018)
CLINICS AVAILABLE AT RATIONAL PHARMACY CLINICS AVAILABLE  AT RATIONAL PHARMACY , VALLEY ROAD,  B'KARA ... (19 Nov 2018)
Monday, 27 November 2017 22:18

Hormone therapy in the menopause transition does not increase risk of stroke Featured

Rate this item
(0 votes)

Postmenopausal hormone therapy is not associated with increased risk of stroke, provided that it is started early, according to a report from Karolinska Institutet in Sweden published in the journal PLOS Medicine.


Roughly three in ten women in the menopause transition are afflicted by symptoms that seriously affect their wellbeing, such as hot flushes, dry mucosa and insomnia. However, although the symptoms can be treated effectively with female sex hormones, prescriptions have been low over the past 15 years as researchers have demonstrated a link between such therapy and an increased risk of certain diseases, including stroke.

There is still, however, a need for more research on the issue, as the risk can be influenced by the time of the treatment and other factors, reasons Karin Leander, researcher at Karolinska Institutet’s Institute of Environmental Medicine.

“New research shows us that hormone therapy actually has a positive effect on blood vessels if initiated early on in the menopause, but not if initiated late,” says Dr Leander. “So there was reason to re-examine whether hormone therapy is linked to the risk of stroke, taking, of course, the time of administering into consideration.”

Dr Leander and her colleagues have now analysed data on postmenopausal hormone therapy from five Swedish cohort studies covering a total of 88,914 women, combined with data from national registries on diagnoses and causes of death during a follow-up period.

Hormone therapy was not linked to increased risk of stroke (ischemic and haemorrhagic stroke combined) if the therapy was initiated within five years of menopausal onset, regardless of means of administration (oral, via the skin or vaginal), type of therapy (combination or oestrogen only), active substance and treatment duration.

In sub-analyses, however, there was an observable increase in risk for haemorrhagic stroke (the less common form) if the therapy contained the active substance conjugated equine oestrogens. Drugs containing oestradiol, on the other hand, were not associated with a higher risk. A higher risk was also seen for both ischemic and haemorrhagic stroke if the treatment was initiated later than five years after the onset of menopause and contained conjugated equine oestrogens.

“The risk of stroke seems virtually eradicable if treatment commences early, but it’s naturally important to take account of the increase in risk that exists under certain circumstances,” says Dr Leander. “These results provide doctors with a better scientific base on which to take decisions on treatment for menopausal symptoms.”


Source: Karolinska Institutet
Full bibliographic information:
Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies”. Plos Medicine, online 17 November 2017

Read 1257 times Last modified on Tuesday, 28 November 2017 18:40

Latest news

Highlights

  • CLINICS AVAILABLE AT RATIONAL PHARMACY

    CLINICS AVAILABLE  AT RATIONAL PHARMACY , VALLEY ROAD,  B'KARA FOR CONSULTANTS .  GENERAL PRACTITIONER REQUIRED MORNINGS AND AFTERNOONS.

    Written on November 19, 2018

Join

Connect with other Medical Professionals on fb in a closed facebook group

captcha  

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…